In recent years, monoclonal antibody, double antibody, ADC, CAR-T drugs targeting CD19 have been marketed, providing a variety of treatment methods for patients with advanced B-cell lymphoma [33]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.